Acumen Research and Consulting Recombinant Plasma Protein Therapeutics Market | Page 6

2.8. Competitive Landscape, 2017 2.8.1. Player Positioning Analysis 2.8.2. Key Strategies Adopted By Leading Players CHAPTER 3. MANUFACTURING PLANTS ANALYSIS 3.1. Capacity and Commercial Production Date of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017 3.2. Manufacturing Plants Distribution of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017 3.3. R&D Status and Technology Source of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017 3.4. Raw Materials Sources Analysis of Global Recombinant Plasma Protein Therapeutics Major Manufacturers in 2017 CHAPTER 4. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY DRUG CLASS 4.1. Global Recombinant Plasma Protein Therapeutics Revenue By Drug Class 4.2. Human C1 Esterase Inhibitor 4.2.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.2.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.3. Recombinant Coagulation Factors 4.3.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.3.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) 4.4. Other 4.4.1. Market Revenue and Growth Rate, 2015 – 2026 ($Million) 4.4.2. Market Revenue and Forecast, By Region, 2015 – 2026 ($Million) CHAPTER 5. RECOMBINANT PLASMA PROTEIN THERAPEUTICS MARKET BY CELL LINE 5.1. Global Recombinant Plasma Protein Therapeutics Revenue By Cell Line 5.2. Chinese Hamster Ovary (CHO) Cell Line Would like to place an order or any question, please feel free to contact at [email protected] | [phone]